Addisons Disease Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Glucocorticoid, Mineralocorticoid, and Others); Route of Administration (Oral, Parenteral, and Others); End Use (Hospitals, Homecare, Specialty Clinics, and Others), and Geography

Report Code: TIPRE00023421 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

Addisons Disease drugs, also termed hypocortisolism or primary adrenal insufficiency, are potentially life-threatening conditions in which the body does not produce enough cortisol or aldosterone. The characteristics sign and symptoms of Addisons Disease fatigue, nausea, darkening of the skin, and dizziness. Addisons Disease demands lifelong treatment with steroid replacement therapy. Glucocorticoid and mineralocorticoid replacement therapy is presently most widely used for the treatment of Addisons Disease. Additional, hydrocortisone is one of the most preferred drugs belonging to the glucocorticoid class due to its short half-life, which enables it to be quickly absorbed into the bloodstream.

MARKET SCOPE

The "Global Addisons Disease drugs Market Analysis to 2028" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Addisons Disease drugs market with detailed market segmentation by drug class, route of administration, end use, and geography. The report provides key statistics on the market status of the leading Addisons Disease drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •  Based on drug class, the global Addisons Disease drugs market is segmented into glucocorticoid, mineralocorticoid and others.
  •  On the basis of route of administration, the market is segmented into oral, parenteral and others.
  •  On the basis of end use, the market is segmented into hospitals, homecare, specialty clinics and others.

MARKET DYNAMICS
Drivers

  •  Growing cases of Addisons Disease.
  •  Rise in the research and development activities by pharmaceutical companies.
  •  Rise in patient awareness.
  •  Advancements in treatment options.

Restraints

  •  The product recalls and misuse of drug are the major restraining factor for this market.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Addisons Disease drugs market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Addisons Disease drugs market in these regions.

IMPACT OF COVID-19 ON Addisons Disease DRUGS MARKET

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Addisons Disease drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Addisons Disease drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for Addisons Disease drugs in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Addisons Disease drugs market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •  Bristol-Myers Squibb Company
  •  Merck and Co., Inc
  •  Novartis AG
  •  Pfizer Inc
  •  Takeda Pharmaceutical Company Limited
  •  Bio-Techne
  •  GlaxoSmithKline plc
  •  Lupin
  •  Abbott
  •  Amgen Inc

The Insight Partner's dediAddisons Disease drugsed research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Addisons Disease Drugs Market - By Drug Class
1.3.2 Addisons Disease Drugs Market - By Route of Administration
1.3.3 Addisons Disease Drugs Market - By End Use
1.3.4 Addisons Disease Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. Addisons Disease DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. Addisons Disease DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. Addisons Disease DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. Addisons Disease DRUGS - GLOBAL MARKET OVERVIEW
6.2. Addisons Disease DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. Addisons Disease DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. GLUCOCORTICOID
7.3.1. Overview
7.3.2. Glucocorticoid Market Forecast and Analysis
7.4. MINERALOCORTICOID
7.4.1. Overview
7.4.2. Mineralocorticoid Market Forecast and Analysis
7.5. OTHERS
7.5.1. Overview
7.5.2. Others Market Forecast and Analysis
8. Addisons Disease DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. PARENTERAL
8.4.1. Overview
8.4.2. Parenteral Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. Addisons Disease DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - END USE
9.1. OVERVIEW
9.2. END USE MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. HOMECARE
9.4.1. Overview
9.4.2. Homecare Market Forecast and Analysis
9.5. SPECIALTY CLINICS
9.5.1. Overview
9.5.2. Specialty Clinics Market Forecast and Analysis
9.6. OTHERS
9.6.1. Overview
9.6.2. Others Market Forecast and Analysis
10. Addisons Disease DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Addisons Disease Drugs Market Overview
10.1.2 North America Addisons Disease Drugs Market Forecasts and Analysis
10.1.3 North America Addisons Disease Drugs Market Forecasts and Analysis - By Drug Class
10.1.4 North America Addisons Disease Drugs Market Forecasts and Analysis - By Route of Administration
10.1.5 North America Addisons Disease Drugs Market Forecasts and Analysis - By End Use
10.1.6 North America Addisons Disease Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Addisons Disease Drugs Market
10.1.6.1.1 United States Addisons Disease Drugs Market by Drug Class
10.1.6.1.2 United States Addisons Disease Drugs Market by Route of Administration
10.1.6.1.3 United States Addisons Disease Drugs Market by End Use
10.1.6.2 Canada Addisons Disease Drugs Market
10.1.6.2.1 Canada Addisons Disease Drugs Market by Drug Class
10.1.6.2.2 Canada Addisons Disease Drugs Market by Route of Administration
10.1.6.2.3 Canada Addisons Disease Drugs Market by End Use
10.1.6.3 Mexico Addisons Disease Drugs Market
10.1.6.3.1 Mexico Addisons Disease Drugs Market by Drug Class
10.1.6.3.2 Mexico Addisons Disease Drugs Market by Route of Administration
10.1.6.3.3 Mexico Addisons Disease Drugs Market by End Use
10.2. EUROPE
10.2.1 Europe Addisons Disease Drugs Market Overview
10.2.2 Europe Addisons Disease Drugs Market Forecasts and Analysis
10.2.3 Europe Addisons Disease Drugs Market Forecasts and Analysis - By Drug Class
10.2.4 Europe Addisons Disease Drugs Market Forecasts and Analysis - By Route of Administration
10.2.5 Europe Addisons Disease Drugs Market Forecasts and Analysis - By End Use
10.2.6 Europe Addisons Disease Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Addisons Disease Drugs Market
10.2.6.1.1 Germany Addisons Disease Drugs Market by Drug Class
10.2.6.1.2 Germany Addisons Disease Drugs Market by Route of Administration
10.2.6.1.3 Germany Addisons Disease Drugs Market by End Use
10.2.6.2 France Addisons Disease Drugs Market
10.2.6.2.1 France Addisons Disease Drugs Market by Drug Class
10.2.6.2.2 France Addisons Disease Drugs Market by Route of Administration
10.2.6.2.3 France Addisons Disease Drugs Market by End Use
10.2.6.3 Spain Addisons Disease Drugs Market
10.2.6.3.1 Spain Addisons Disease Drugs Market by Drug Class
10.2.6.3.2 Spain Addisons Disease Drugs Market by Route of Administration
10.2.6.3.3 Spain Addisons Disease Drugs Market by End Use
10.2.6.4 United Kingdom Addisons Disease Drugs Market
10.2.6.4.1 United Kingdom Addisons Disease Drugs Market by Drug Class
10.2.6.4.2 United Kingdom Addisons Disease Drugs Market by Route of Administration
10.2.6.4.3 United Kingdom Addisons Disease Drugs Market by End Use
10.2.6.5 Rest of Europe Addisons Disease Drugs Market
10.2.6.5.1 Rest of Europe Addisons Disease Drugs Market by Drug Class
10.2.6.5.2 Rest of Europe Addisons Disease Drugs Market by Route of Administration
10.2.6.5.3 Rest of Europe Addisons Disease Drugs Market by End Use
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Addisons Disease Drugs Market Overview
10.3.2 Asia-Pacific Addisons Disease Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Addisons Disease Drugs Market Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Addisons Disease Drugs Market Forecasts and Analysis - By Route of Administration
10.3.5 Asia-Pacific Addisons Disease Drugs Market Forecasts and Analysis - By End Use
10.3.6 Asia-Pacific Addisons Disease Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Addisons Disease Drugs Market
10.3.6.1.1 Australia Addisons Disease Drugs Market by Drug Class
10.3.6.1.2 Australia Addisons Disease Drugs Market by Route of Administration
10.3.6.1.3 Australia Addisons Disease Drugs Market by End Use
10.3.6.2 China Addisons Disease Drugs Market
10.3.6.2.1 China Addisons Disease Drugs Market by Drug Class
10.3.6.2.2 China Addisons Disease Drugs Market by Route of Administration
10.3.6.2.3 China Addisons Disease Drugs Market by End Use
10.3.6.3 India Addisons Disease Drugs Market
10.3.6.3.1 India Addisons Disease Drugs Market by Drug Class
10.3.6.3.2 India Addisons Disease Drugs Market by Route of Administration
10.3.6.3.3 India Addisons Disease Drugs Market by End Use
10.3.6.4 Japan Addisons Disease Drugs Market
10.3.6.4.1 Japan Addisons Disease Drugs Market by Drug Class
10.3.6.4.2 Japan Addisons Disease Drugs Market by Route of Administration
10.3.6.4.3 Japan Addisons Disease Drugs Market by End Use
10.3.6.5 South Korea Addisons Disease Drugs Market
10.3.6.5.1 South Korea Addisons Disease Drugs Market by Drug Class
10.3.6.5.2 South Korea Addisons Disease Drugs Market by Route of Administration
10.3.6.5.3 South Korea Addisons Disease Drugs Market by End Use
10.3.6.6 Rest of Asia-Pacific Addisons Disease Drugs Market
10.3.6.6.1 Rest of Asia-Pacific Addisons Disease Drugs Market by Drug Class
10.3.6.6.2 Rest of Asia-Pacific Addisons Disease Drugs Market by Route of Administration
10.3.6.6.3 Rest of Asia-Pacific Addisons Disease Drugs Market by End Use
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Addisons Disease Drugs Market Overview
10.4.2 Middle East and Africa Addisons Disease Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Addisons Disease Drugs Market Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Addisons Disease Drugs Market Forecasts and Analysis - By Route of Administration
10.4.5 Middle East and Africa Addisons Disease Drugs Market Forecasts and Analysis - By End Use
10.4.6 Middle East and Africa Addisons Disease Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Addisons Disease Drugs Market
10.4.6.1.1 South Africa Addisons Disease Drugs Market by Drug Class
10.4.6.1.2 South Africa Addisons Disease Drugs Market by Route of Administration
10.4.6.1.3 South Africa Addisons Disease Drugs Market by End Use
10.4.6.2 Saudi Arabia Addisons Disease Drugs Market
10.4.6.2.1 Saudi Arabia Addisons Disease Drugs Market by Drug Class
10.4.6.2.2 Saudi Arabia Addisons Disease Drugs Market by Route of Administration
10.4.6.2.3 Saudi Arabia Addisons Disease Drugs Market by End Use
10.4.6.3 U.A.E Addisons Disease Drugs Market
10.4.6.3.1 U.A.E Addisons Disease Drugs Market by Drug Class
10.4.6.3.2 U.A.E Addisons Disease Drugs Market by Route of Administration
10.4.6.3.3 U.A.E Addisons Disease Drugs Market by End Use
10.4.6.4 Rest of Middle East and Africa Addisons Disease Drugs Market
10.4.6.4.1 Rest of Middle East and Africa Addisons Disease Drugs Market by Drug Class
10.4.6.4.2 Rest of Middle East and Africa Addisons Disease Drugs Market by Route of Administration
10.4.6.4.3 Rest of Middle East and Africa Addisons Disease Drugs Market by End Use
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Addisons Disease Drugs Market Overview
10.5.2 South and Central America Addisons Disease Drugs Market Forecasts and Analysis
10.5.3 South and Central America Addisons Disease Drugs Market Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Addisons Disease Drugs Market Forecasts and Analysis - By Route of Administration
10.5.5 South and Central America Addisons Disease Drugs Market Forecasts and Analysis - By End Use
10.5.6 South and Central America Addisons Disease Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Addisons Disease Drugs Market
10.5.6.1.1 Brazil Addisons Disease Drugs Market by Drug Class
10.5.6.1.2 Brazil Addisons Disease Drugs Market by Route of Administration
10.5.6.1.3 Brazil Addisons Disease Drugs Market by End Use
10.5.6.2 Argentina Addisons Disease Drugs Market
10.5.6.2.1 Argentina Addisons Disease Drugs Market by Drug Class
10.5.6.2.2 Argentina Addisons Disease Drugs Market by Route of Administration
10.5.6.2.3 Argentina Addisons Disease Drugs Market by End Use
10.5.6.3 Rest of South and Central America Addisons Disease Drugs Market
10.5.6.3.1 Rest of South and Central America Addisons Disease Drugs Market by Drug Class
10.5.6.3.2 Rest of South and Central America Addisons Disease Drugs Market by Route of Administration
10.5.6.3.3 Rest of South and Central America Addisons Disease Drugs Market by End Use
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL Addisons Disease DRUGS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. Addisons Disease DRUGS MARKET, KEY COMPANY PROFILES
13.1. BRISTOL MYERS SQUIBB COMPANY
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. MERCK AND CO., INC
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. NOVARTIS AG
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. PFIZER INC
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. TAKEDA PHARMACEUTICAL COMPANY LIMITED
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. BIO TECHNE
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. GLAXOSMITHKLINE PLC
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. LUPIN
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. ABBOTT
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. AMGEN INC
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Bristol-Myers Squibb Company
2. Merck and Co., Inc
3. Novartis AG
4. Pfizer Inc
5. Takeda Pharmaceutical Company Limited
6. Bio-Techne
7. GlaxoSmithKline plc
8. Lupin
9. Abbott
10. Amgen Inc
11. Bayer AG
12. Biogen
13. Eli Lilly and Company
14. ViroPharma
15. Tocris Bioscience
TIPRE00023421
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking